[go: up one dir, main page]

AU2024260120A1 - Influenza virus vaccines - Google Patents

Influenza virus vaccines

Info

Publication number
AU2024260120A1
AU2024260120A1 AU2024260120A AU2024260120A AU2024260120A1 AU 2024260120 A1 AU2024260120 A1 AU 2024260120A1 AU 2024260120 A AU2024260120 A AU 2024260120A AU 2024260120 A AU2024260120 A AU 2024260120A AU 2024260120 A1 AU2024260120 A1 AU 2024260120A1
Authority
AU
Australia
Prior art keywords
influenza virus
virus vaccines
vaccines
influenza
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024260120A
Inventor
Zsófia BITTNER-SCHRADER
Badiaa BOUZYA
Edith JASNY
Romuald MASCOLO
Marie-Cécile Claudine MORTIER
Nadia Ouaked
Benjamin Petsch
Lionel Julien SACCONNAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2306220.1A external-priority patent/GB202306220D0/en
Priority claimed from GBGB2314629.3A external-priority patent/GB202314629D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2024260120A1 publication Critical patent/AU2024260120A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2024260120A 2023-04-27 2024-04-25 Influenza virus vaccines Pending AU2024260120A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2306220.1A GB202306220D0 (en) 2023-04-27 2023-04-27 Influenza virus vaccines
GB2306220.1 2023-04-27
GB2314629.3 2023-09-25
GBGB2314629.3A GB202314629D0 (en) 2023-09-25 2023-09-25 Influenza virus vaccines
PCT/EP2024/061356 WO2024223728A1 (en) 2023-04-27 2024-04-25 Influenza virus vaccines

Publications (1)

Publication Number Publication Date
AU2024260120A1 true AU2024260120A1 (en) 2025-11-06

Family

ID=90924479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024260120A Pending AU2024260120A1 (en) 2023-04-27 2024-04-25 Influenza virus vaccines

Country Status (3)

Country Link
CN (1) CN121001738A (en)
AU (1) AU2024260120A1 (en)
WO (1) WO2024223728A1 (en)

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
US7514099B2 (en) 2005-02-14 2009-04-07 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
ATE291925T1 (en) 2001-06-05 2005-04-15 Curevac Gmbh STABILIZED MRNA WITH INCREASED G/C CONTENT AND OPTIMIZED CODON USAGE FOR GENE THERAPY
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
JP2009544754A (en) 2006-07-28 2009-12-17 アプライド バイオシステムズ， エルエルシー Dinucleotide MRNA cap analog
DE102006061015A1 (en) 2006-12-22 2008-06-26 Curevac Gmbh Process for the purification of RNA on a preparative scale by HPLC
CA2689042A1 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
CA2692906C (en) 2007-06-19 2016-01-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
CA3044134A1 (en) 2008-01-02 2009-07-09 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
PL2279254T3 (en) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
PL215513B1 (en) 2008-06-06 2013-12-31 Univ Warszawski New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein
US20110224447A1 (en) 2008-08-18 2011-09-15 Bowman Keith A Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids
WO2010042877A1 (en) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
KR101734955B1 (en) 2008-11-07 2017-05-12 메사추세츠 인스티튜트 오브 테크놀로지 Aminoalcohol lipidoids and uses thereof
KR102760023B1 (en) 2008-11-10 2025-01-31 알닐람 파마슈티칼스 인코포레이티드 Novel lipids and compositions for the delivery of therapeutics
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
NZ596186A (en) 2009-05-05 2014-03-28 Alnylam Pharmaceuticals Inc Lipid compositions
PT2440183T (en) 2009-06-10 2018-10-30 Arbutus Biopharma Corp Improved lipid formulation
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
EP3072881A1 (en) 2009-08-20 2016-09-28 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
US20120253032A1 (en) 2009-10-08 2012-10-04 Merck Sharp & Dohme Corporation Novel cationic lipids with short lipid chains for oligonucleotide delivery
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
EA026374B1 (en) 2009-12-23 2017-04-28 Новартис Аг Lipids, lipid compositions, and methods of using them
EP2525781A1 (en) 2010-01-22 2012-11-28 Schering Corporation Novel cationic lipids for oligonucleotide delivery
US9254327B2 (en) 2010-05-10 2016-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
EP2575895A2 (en) 2010-05-24 2013-04-10 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
EP3254672B1 (en) 2010-06-03 2025-08-20 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2011153120A1 (en) 2010-06-04 2011-12-08 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
MX342608B (en) 2010-07-06 2016-10-06 Novartis Ag * Virion-like delivery particles for self-replicating rna molecules.
SI2590626T1 (en) 2010-07-06 2016-01-29 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pka-value for rna delivery
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
AU2011295938B2 (en) 2010-08-31 2016-01-14 Glaxosmithkline Biologicals S.A. Lipids suitable for liposomal delivery of protein-coding RNA
LT4226941T (en) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
PL4043040T3 (en) 2010-08-31 2023-04-17 Glaxosmithkline Biologicals Sa Small liposomes for delivery of immunogen-encoding rna
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
WO2012040184A2 (en) 2010-09-20 2012-03-29 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
KR20130114115A (en) 2010-09-30 2013-10-16 머크 샤프 앤드 돔 코포레이션 Low molecular weight cationic lipids for oligonucleotide delivery
US9029590B2 (en) 2010-10-21 2015-05-12 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
DK2635265T3 (en) 2010-11-05 2018-07-16 Sirna Therapeutics Inc New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
EP3336082B1 (en) 2011-06-08 2020-04-15 Translate Bio, Inc. Cleavable lipids
HK1199206A1 (en) 2011-06-08 2015-06-26 夏尔人类遗传性治疗公司 Lipid nanoparticle compositions and methods for mrna delivery
RU2014104090A (en) 2011-07-06 2015-08-20 Новартис Аг LIPOSOMES WITH AN EFFECTIVE N: P RATIO FOR DELIVERY OF PHK MOLECULES
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
HRP20190032T1 (en) 2011-08-31 2019-02-22 Glaxosmithkline Biologicals Sa PEGILATED LIPOSOMS, INTENDED FOR RNA IMPROVEMENT, CODING IMMUNOGEN
US8969545B2 (en) 2011-10-18 2015-03-03 Life Technologies Corporation Alkynyl-derivatized cap analogs, preparation and uses thereof
MX363734B (en) 2011-10-27 2019-03-29 Massachusetts Inst Technology Amino acid derivates functionalized on the n- terminal capable of forming drug incapsulating microspheres.
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
CA2856742A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
JP6182457B2 (en) 2011-12-12 2017-08-16 協和発酵キリン株式会社 Lipid nanoparticles for drug delivery systems containing cationic lipids
MX358706B (en) 2012-03-27 2018-08-31 Curevac Ag Artificial nucleic acid molecules comprising a 5'top utr.
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
US9970047B2 (en) 2013-03-14 2018-05-15 Translate Bio, Inc. Quantitative assessment for cap efficiency of messenger RNA
ES2997341T3 (en) 2013-03-14 2025-02-17 Translate Bio Inc Quantitative assessment for cap efficiency of messenger rna
SG11201602943PA (en) 2013-10-22 2016-05-30 Shire Human Genetic Therapies Lipid formulations for delivery of messenger rna
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
EP3071547B1 (en) 2013-11-18 2024-07-10 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
ES2908827T3 (en) 2013-12-19 2022-05-04 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3623361B1 (en) 2013-12-19 2021-08-18 Novartis AG Lipids and lipid compositions for the delivery of active agents
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
CN106661621B (en) 2014-06-10 2020-11-03 库尔维科公司 Methods and tools for enhanced RNA production
HRP20221536T1 (en) 2014-06-25 2023-02-17 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016022914A1 (en) 2014-08-08 2016-02-11 Moderna Therapeutics, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
CN107072946B (en) 2014-09-05 2022-01-11 诺华股份有限公司 Lipids and lipid compositions for delivery of active agents
SG10201906673WA (en) 2014-12-30 2019-09-27 Curevac Ag Artificial nucleic acid molecules
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP4026568A1 (en) 2015-04-17 2022-07-13 CureVac Real Estate GmbH Lyophilization of rna
US11384375B2 (en) 2015-04-30 2022-07-12 Curevac Ag Immobilized poly(n)polymerase
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
CN107635587A (en) 2015-05-20 2018-01-26 库瑞瓦格股份公司 Include long-chain RNA dry powder compositions
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
DK3303583T3 (en) 2015-05-29 2020-07-13 Curevac Real Estate Gmbh METHOD FOR PREPARATION AND PURIFICATION OF RNA, INCLUDING AT LEAST ONE STEP FOR TANGENTIAL FLOW FILTRATION
WO2016193226A1 (en) 2015-05-29 2016-12-08 Curevac Ag Method for adding cap structures to rna using immobilized enzymes
CA2992801A1 (en) 2015-08-28 2017-03-09 Curevac Ag Artificial nucleic acid molecules
DK3954225T5 (en) 2015-09-21 2024-08-05 Trilink Biotechnologies Llc Initiating capped oligonucleotide primers for synthesizing 5' capped RNA
EP3362460A1 (en) 2015-10-16 2018-08-22 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
WO2017066797A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
US20190218546A1 (en) 2015-10-16 2019-07-18 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE CYTOMEGALOVIRUS HUMAN
JP7384512B2 (en) 2015-10-22 2023-11-21 モデルナティエックス インコーポレイテッド Broad-spectrum influenza virus vaccine
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
SI3386484T1 (en) 2015-12-10 2022-06-30 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
EP3394030B2 (en) 2015-12-22 2025-02-12 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
WO2017109161A1 (en) 2015-12-23 2017-06-29 Curevac Ag Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
AU2017350488B2 (en) 2016-10-26 2022-06-23 Acuitas Therapeutics Inc. Lipid nanoparticle mRNA vaccines
JP6944231B2 (en) 2017-06-27 2021-10-06 花王株式会社 Abrasive liquid composition
CA3073634A1 (en) 2017-10-19 2019-04-25 Curevac Ag Novel artificial nucleic acid molecules
CN111511924A (en) 2017-11-08 2020-08-07 库瑞瓦格股份公司 RNA-seq adjustment
EP3813874A1 (en) 2018-06-27 2021-05-05 CureVac AG Novel lassa virus rna molecules and compositions for vaccination
CA3160511A1 (en) 2020-02-04 2021-08-12 Susanne RAUCH Coronavirus vaccine
AU2021260578A1 (en) 2020-04-20 2022-11-03 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
IL300519A (en) 2020-08-14 2023-04-01 Arcturus Therapeutics Inc Method of lyophilizing lipid nanoparticles
AU2021358777A1 (en) 2020-10-06 2023-06-15 Translate Bio, Inc. Improved process and formulation of lipid nanoparticles
TW202233232A (en) * 2020-11-06 2022-09-01 法商賽諾菲公司 Lipid nanoparticles for delivering mrna vaccines
CA3198538A1 (en) 2020-11-16 2022-05-19 Bakul Subodh BHATNAGAR Enhanced formulation stabilization and improved lyophilization processes
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
WO2022232585A1 (en) 2021-04-29 2022-11-03 Modernatx, Inc. Lyophilization methods for preparing lipid formulated therapeutics
EP4355308A1 (en) * 2021-06-18 2024-04-24 Sanofi Multivalent influenza vaccines

Also Published As

Publication number Publication date
CN121001738A (en) 2025-11-21
WO2024223728A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
GB2592769B (en) CpG-Adjuvanted SARS-CoV-2 virus vaccine
EP4126032A4 (en) Universal influenza vaccine using nucleoside-modifield mrna
EP3814509A4 (en) Influenza virus hemagglutinin mutants
GB202004825D0 (en) Influenza vaccines
EP3939607A4 (en) Dengue virus vaccine
AU2024260120A1 (en) Influenza virus vaccines
HK40122964A (en) Influenza virus vaccines
AU2022257033A1 (en) Pseudorabies virus vaccine
AU2022234358A1 (en) Polysaccharide adjuvants for virus vaccines
GB202314629D0 (en) Influenza virus vaccines
GB202306220D0 (en) Influenza virus vaccines
HK40102659A (en) Virus vaccine
HK40107994A (en) Virus vaccine
HK40060643A (en) Inactivated sars-cov-2 virus vaccine
HK40090677A (en) Influenza vaccines
HK40089378A (en) Influenza virus backbone
HK40079962A (en) Influenza virus vaccines and uses thereof
HK40078791A (en) Influenza virus vaccines and uses thereof
HK40111931A (en) Viral vaccine
HK40107508A (en) Pseudorabies virus vaccine
HK40070131A (en) Influenza virus backbone
AU2023901936A0 (en) Multivalent subtype influenza vaccine
GB202315888D0 (en) Influenza vaccines
GB202213958D0 (en) Influenza vaccines
GB202208070D0 (en) Influenza vaccines